Andere talen Arvinas, Inc.

Aandelen

ARVN

US04335A1051

Biotechnologie & Medisch Onderzoek

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-06-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,740 ^USD	+4,59%		+3,48%	-59,62%

17/06	Logos Global Management LP Richt Brief aan Raad van Bestuur van Arvinas, Inc.	CI
13/06	Arvinas, Inc. Presenteert Preklinische Gegevens voor PROTAC BCL6 Afbreker, ARV-393, op het European Hematology Association 2025 Congres	CI

Andere talen

Logos Global Management LP Issues a Letter to the Board of Arvinas, Inc.	17/06
Arvinas, Inc. Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress	13/06
Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma	13/06
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress	13/06
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN	07/06
Arvinas, Inc. Announces Resignation of Ian Taylor as President of Research and Development, Effective June 6, 2025	06/06
Sector Update: Health Care Stocks Advance Premarket Friday	06/06
Arvinas, Pfizer Seek FDA Approval of Vepdegestrant in Breast Cancer	06/06
Arvinas and Pfizer Announce Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer	06/06
Arvinas, Pfizer Submit New Drug Application for Vepdegestrant as Breast Cancer Treatment	06/06
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer	06/06
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer	06/06
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting	05/06
Wall Street Monitors Global Trade Situation as US Equity Futures Move Lower Pre-Bell	02/06
USA-Les valeurs à suivre à Wall Street (actualisé)	02/06
Arvinas, Pfizer Report Breast Cancer Treatment Phase 3 Trial Results; Arvinas Shares Down Pre-Bell	02/06
Les valeurs à suivre à Paris et en Europe (actualisé)	02/06
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN	01/06
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression	31/05
Arvinas And Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival For Patients With Esr1-Mutant, Er+/Her2- Advanced Breast Cancer	31/05
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer	31/05
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer	31/05
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients Withesr1-Mutant, Er+/Her2- Advanced Breast Cancer	31/05
Arvinas to Present at Jefferies Global Healthcare Conference	30/05
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN)	29/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Arvinas, Inc.

Aandelen

ARVN

US04335A1051

Biotechnologie & Medisch Onderzoek

Andere talen

Filters